Hamilton Health Sciences Corp.

Critically ill patients are at risk of stress-induced upper gastrointestinal bleeding. Now, a global trial confirms that a widely available drug does prevent upper gastrointestinal bleeding. A widely available drug helps prevent upper gastrointestinal bleeding in critically ill adults on a breathing machine, according to the results of a global study and meta-analysis led by researchers at McMaster University. The research, published on June 14, 2024 in The New England Journal of Medicine and NEJM Evidence, investigated the effect of the gastric acid suppressant pantoprazole, which is primarily used to treat heartburn caused by gastroesophageal reflux disease (GERD). Patients in the intensive care unit (ICU) who need a breathing machine (mechanical ventilator) also receive pantoprazole to prevent upper gastrointestinal bleeding, caused by stress-induced ulcers in the stomach. Concerns emerged about whether this complication of critical illness had disappeared over the years, and about side effects of pantoprazole, including increased risk of death in the sickest patients. The research provides critical care teams with certainty about whether the medications should be used in practice. "This is the largest randomized trial on this topic in the world, led by Canada. Physicians, nurses, and pharmacists working in the ICU setting will use this information in practice right away, and the trial results and the updated meta-analysis will be incorporated into international practice guidelines," said lead author and principal investigator Deborah Cook, a professor in the Department of Medicine at McMaster. Global randomized control trial The Reevaluating the Inhibition of Stress Erosions (REVISE) Trial was a randomized control trial that compared the effect of pantoprazole to placebo in critically ill adults on a breathing machine. The trial was run in 68 centres in eight countries and over 4,800 patients underwent randomization. Among patients undergoing invasive ventilation, pantoprazole resulted in a significantly lower risk of clinically important upper gastrointestinal bleeding than placebo but not in a lower risk of death. Clinically important upper gastrointestinal bleeding occurred in 25 of 2,417 patients (one per cent) receiving pantoprazole and in 84 of 2404 patients (nearly four per cent) receiving placebo. At 90 days, death was reported in 696 of 2390 patients (29 per cent) in the pantoprazole group and in 734 of 2379 patients (30 per cent) in the placebo group. Updated systematic review Researchers conducted a meta-analysis of 12 randomized trials of proton-pump inhibitors for GI bleeding prevention in 10,000 critically ill patients to summarize the current evidence on the outcomes of gastrointestinal bleeding, mortality, pneumonia and C. difficile infection. The medications were associated with a reduced incidence of clinically important upper gastrointestinal bleeding and may have little or no effect on mortality. The evidence also showed the medications may have no effect on pneumonia and little or no effect on C. difficile infection. The research was funded by the Canadian Institutes for Health Research, the Accelerating Clinical Trials Fund, Physicians Services Incorporated of Ontario, Hamilton Association of Health Sciences Organization, and the National Health Medical Research Council of Australia.

Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high throughput optical genome mapping (OGM) and findings from early access customersThe pre-conference event will also include a 2024 corporate overview from Bionano’s chief executive officer, Dr. Erik Holmlin, presentations from Dr. Brynn Levy at Columbia University Medical Center, Dr. Ulrich Broeckel at Medical College of Wisconsin, Dr. Susan Crocker at Kingston Health Sciences Centre, Dr. Liz McCready at Hamilton Health Science Center, and Dr. Zeid Hamadeh at Vancouver General Hospital covering the utility of OGM and VIA™ software and the adoption, implementation, and advanced research capabilities of the Stratys system, and will conclude with a fireside chat with panelists hosted by Bionano’s chief medical officer, Dr. Alka ChaubeyIn a sponsored session, Dr. Chaubey will cover findings from large multi-site clinical studies using OGM as well as features of the Stratys system. Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis A scientific platform presentation will feature Drs. Hamadeh and Spence discussing OGM’s utility for the genotyping of hematological neoplasmsDr. Holmlin will participate with Dr. Nancy Mendelsohn, president of the ACMG Foundation, in the foundation’s educational and clinical laboratory genetics and genomics (LGG) awards ceremony by presenting the fellowship awards sponsored by BionanoEleven scientific posters featuring results from OGM applications in cancer, postnatal applications and genetic disorders will be presented at the conference SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2024 with a broad range of content covering optical genome mapping’s (OGM) utility for research areas including cancer, rare genetic disease and constitutional disorders. ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. The ACMG conference will be held March 12-16, 2024, in Toronto, Canada. All scientific posters will be presented in Exhibit Halls DE. Poster presentations and scientific workshop sessions on OGM include: Poster Number Title AuthorsPresentedP573 Genome-wide short tandem repeat expansion screening using optical genome mapping Yu J.March 14, 202410:30 AM-12:00 PM ETP583 Clinical utility of optical genome mapping as an additional test to standard cytogenetic workup of hematological malignancies Toruner G.March 14, 202410:30 AM- 12:00 PM ETP839 A curated research catalogue of structural variation detected by optical genome mapping Pang A.March 14, 202410:30 AM-12:00 PM ETP088 A comprehensive approach to evaluate genetic abnormalities in plasma cell neoplasms using optical genome mapping and next-generation sequencing Zou Y.March 15, 202410:30 AM-12:00 PM ETP608 Optical genome mapping for genome-wide structural variation analysis in hematologic malignancies: results of a prospective study and potential impact on diagnosis and management Sahoo T.March 15, 202410:30 AM-12:00 PM ETP656 Improved diagnostic paradigm using optical genome mapping (OGM) for cytogenomic testing for recurrent pregnancy loss and infertility Crocker S.March 15, 202410:30 AM-12:00 PM ETP694 Case report: unraveling a complex chromosomal rearrangement case using optical genome mapping Ozcan Z.March 15, 202410:30 AM- 12:00 PM ETP742 Assessing stability of frozen samples for Bionano optical single DNA mapping for diagnosis of Facioscapulohumeral Muscular Dystrophy Type 1 Cook S.March 15, 202410:30 AM-12:00 PM ETP746 Genome wide, high-throughput, high-resolution structural variation detection at low variant allele fraction for oncology samples Hastie A.March 15, 202410:30 AM-12:00 PM ETP842 Unified comprehensive analysis of NGS and optical genome mapping data for constitutional applications using Bionano VIA™ software Norgaard Z.March 15, 202410:30 AM-12:00 PM ETP850 Accelerated optical genome mapping analysis with Stratys Compute and Guided Assembly Senol Cali D.March 15, 202410:30 AM-12:00 PM ETSession Title PresenterPresentedSponsored Workshop LIVE Bionano product showcase – Stratys™ revealed: exclusive first look at the future of OGM Chaubey A., Broeckel U., Crocker S., Hamadeh Z., Holmlin E., Jiandani D., Levy B., McCready L., Sahoo T.March 12, 20248:00 AM- 12:30 PM ETDelta Hotel by Marriott- Kensington BallroomPlenary Session 2024 ACMG Foundation Awards and Presidential Plenary Session Holmlin E.March 13, 202410:00-12:00 PM ETExhibit Hall FGPlatform Presentation A Canadian lab’s clinical validation experience with optical genome mapping as a front-line diagnostic test for hematological neoplasms Hamadeh Z., Spence T.March 14, 20244:15-5:45 PM ETMTCC- 714/716Sponsored Workshop Revolutionizing cytogenomics with Stratys™: unveiling a new frontier in structural variant assessment through optical genome mapping at scale Chaubey A., Spence T.,March 15, 202410:45-11:15 AM ETExhibit Theater 2 Erik Holmlin, PhD, president and chief executive officer of Bionano, added, “We are proud to debut our new high throughput system for OGM, Stratys, at ACMG this year, and to host sessions featuring customers from our Stratys early access program presenting data from work conducted on the system. Researchers and scientists continue to push forward cutting-edge research in the human genetics space and we believe the capabilities of the Stratys system will unlock even more exciting research advancements. We look forward to these customers sharing their findings with the ACMG community.” More details on Bionano’s conference events can be found here. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Bionano’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Bionano offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, Bionano also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Bionano also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Bionano additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology. Forward-Looking Statements of Bionano This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: OGM’s utility for applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2024 Annual Meeting; the ability of the Stratys system to unlock research advancements; and the growth and adoption of OGM. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including bank failures, inflation and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of OGM to prove useful in areas including applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s Annual Meeting; failure of the Stratys system to unlock research advancements; failure of laboratories to adopt OGM; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ACMG’s 2024 Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ACMG’s 2024 Annual Meeting; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com

— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms — Bone turnover markers trended toward the normal reference ranges for sex and menopausal status and corresponded to smaller changes in bone mineral density (BMD) through Week 52 — Results were similar to trends in bone turnover markers and changes in BMD previously reported through Week 110 in the Phase 2 PaTH Forward Trial COPENHAGEN, Denmark, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 52-week data from the open-label extension period of its ongoing Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) showing that adults with chronic hypoparathyroidism, whose bones tend to be over-mineralized due to insufficient parathyroid hormone (PTH) exposure, trended toward a new skeletal steady state closer to age-appropriate norms with continued use of TransCon PTH. The results were consistent regardless of sex, menopausal status, or duration of disease and were consistent with results previously reported through Week 110 in the Company’s Phase 2 PaTH Forward Trial. An oral presentation of the data was given today by Aliya Khan, M.D., Clinical Professor of Medicine at McMaster University and Director of the Calcium Disorders Clinic at McMaster University Medical Center, during ASBMR 2023, the annual meeting of the American Association of Bone & Mineral Research in Vancouver, BC, Canada. Reflecting on the clinical data and its potential impact, Dr. Khan said “Treatment with TransCon PTH in this clinical trial showed the positive physiological effects on bone, in patients treated for the full year as well as in those switching from placebo after the 26-week blinded period. These results underscore the importance of providing the missing hormone to address the significant impacts of hypoparathyroidism, including decreased bone remodeling leading to a dense, over-mineralized bone structure.” TransCon PTH (palopegteriparatide) is an investigational prodrug with sustained release of active parathyroid hormone (PTH [1-34]) administered once daily. On September 14, 2023, TransCon PTH received a positive CHMP opinion recommending approval in the European Union for the treatment of adults with chronic hypoparathyroidism. TransCon PTH is also in development in the United States and Japan. PaTHway is an ongoing Phase 3 double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1 (TransCon PTH:placebo) treated for 26 weeks, followed by a 156-week open-label extension period. Registered attendees of ASMBR 2023 conference can access the abstract, poster, and presentation (#1114) through the conference organizer’s website. About Ascendis Pharma A/S Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Germany (Heidelberg and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the potential approval of TransCon PTH in the European Union; (ii) Ascendis’ ability to apply its platform technology to build a leading, fully integrated, global biopharma company; and (iii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, the effects on its business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon® are trademarks owned by the Ascendis Pharma group. © October 2023 Ascendis Pharma A/S. Investor Contacts: Media Contact: Tim Lee Melinda Baker Ascendis Pharma Ascendis Pharma +1 (650) 374-6343 +1 (650) 709-8875 tle@ascendispharma.com media@ascendispharma.com ir@ascendispharma.com Patti Bank ICR Westwicke +1 (415) 513-1284 patti.bank@westwicke.com